Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Catholic Big Data Integration Center, Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Clin Mol Hepatol. 2022 Oct;28(4):754-772. doi: 10.3350/cmh.2021.0394. Epub 2022 Apr 21.
Molecular tests are necessary to stratify cancer patients for targeted therapy. However, high cost and technical barriers limit the application of these tests, hindering optimal treatment. Recently, deep learning (DL) has been applied to predict molecular test results from digitized images of tissue slides. Furthermore, treatment response and prognosis can be predicted from tissue slides using DL. In this review, we summarized DL-based studies regarding the prediction of genetic mutation, microsatellite instability, tumor mutational burden, molecular subtypes, gene expression, treatment response, and prognosis directly from hematoxylin- and eosin-stained tissue slides. Although performance needs to be improved, these studies clearly demonstrated the feasibility of DL-based prediction of key molecular features in cancer tissues. With the accumulation of data and technical advances, the performance of the DL system could be improved in the near future. Therefore, we expect that DL could provide cost- and time-effective alternative tools for patient stratification in the era of precision oncology.
分子检测对于癌症患者的靶向治疗至关重要。然而,高昂的成本和技术障碍限制了这些检测的应用,阻碍了最佳治疗方案的实施。最近,深度学习(DL)已被应用于从组织切片的数字化图像中预测分子检测结果。此外,还可以通过 DL 从组织切片预测治疗反应和预后。在这篇综述中,我们总结了基于 DL 的研究,这些研究直接从苏木精和伊红染色的组织切片中预测遗传突变、微卫星不稳定性、肿瘤突变负担、分子亚型、基因表达、治疗反应和预后。尽管性能有待提高,但这些研究清楚地证明了基于 DL 的癌症组织中关键分子特征预测的可行性。随着数据的积累和技术的进步,DL 系统的性能在不久的将来可能会得到改善。因此,我们预计 DL 可以为精准肿瘤学时代的患者分层提供具有成本效益和时间效益的替代工具。